Pharmaceutical giant GSK- which recently opened a £90million manufacturing facility at its Barnard Castle site – has increased its full-year earnings outlook after surging global demand for its shingles vaccine.
The group – which spun off its consumer healthcare business Haleon in July – posted an 18% rise in sales to £7.8 billion over the third quarter, up 9% on a constant currency basis.
This saw underlying earnings rise 18% to £2.6 billion.
